Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|18|12|964-978

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.18, Iss.12, 2018-03, pp. : 964-978

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors

By  

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 12, 2018-03 ,pp. : 945-963

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease

By  

Current Medicinal Chemistry, Vol. 22, Iss. 38, 2015-12 ,pp. : 4341-4365

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases

By  

Current Pharmaceutical Design, Vol. 16, Iss. 33, 2010-11 ,pp. : 3656-3660

Bentham Science Publishers

Access to resources Recommend Favorite

IL-17 targeted therapies for psoriasis

By Chiricozzi Andrea   Krueger James G  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 8, 2013-08 ,pp. : 993-1005

Informa Healthcare

Access to resources Recommend Favorite

An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis

By  

Current Medicinal Chemistry, Vol. 22, Iss. 16, 2015-05 ,pp. : 1930-1942

Bentham Science Publishers

Access to resources Recommend Favorite